Reuters logo
a month ago
BRIEF-Pfizer receives FDA fast track designation for Tafamidis for transthyretin cardiomyopathy
June 6, 2017 / 12:16 PM / a month ago

BRIEF-Pfizer receives FDA fast track designation for Tafamidis for transthyretin cardiomyopathy

1 Min Read

June 6 (Reuters) - Pfizer Inc

* Pfizer receives FDA fast track designation for tafamidis for transthyretin cardiomyopathy

* Pfizer Inc - ‍Tafamidis, an investigational medicine for ttr-cm, is currently in phase 3 development​

* Pfizer Inc - ‍attr-act study is fully enrolled and is anticipated to be completed in first half of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below